Corey Good­man in­tro­duces Tal­lac Ther­a­peu­tics with a $62M Se­ries A, hop­ing to fight sol­id tu­mors through in­nate and adap­tive im­mu­ni­ty

When West Coast en­tre­pre­neur Corey Good­man and his col­leagues at ALX On­col­o­gy came up with a new idea to po­ten­tial­ly fight can­cer, they knew they had to launch a dis­tinct com­pa­ny for it.

It’s an idea they felt would make the new­ly-pub­lic biotech too crowd­ed, tak­ing nec­es­sary funds away from ex­pand­ing clin­i­cal tri­als for its cen­tral pro­gram tar­get­ing CD47. In­stead of split­ting the re­sources, Good­man and ALX’s now-for­mer CSO Hong Wan want­ed peo­ple ful­ly ded­i­cat­ed to this in­stead of shar­ing the spot­light.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER